Trial Profile

First-in-human, Phase I/II, Multicenter, Open-Label Study of EMB-01 in Patients With Advanced/Metastatic Solid Tumors

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 02 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bafisontamab (Primary)
Indications Colorectal cancer; Gastric cancer; Liver cancer; Non-small cell lung cancer; Solid tumours
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors Epimab Biotherapeutics

Most Recent Events

30 May 2023 Planned End Date changed from 14 Mar 2023 to 15 Jan 2026.
30 May 2023 Planned primary completion date changed from 14 Mar 2023 to 14 Mar 2025.
30 Aug 2021 Planned number of patients changed from 137 to 186.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com